In addition, cancer cells were isolated from mice and then tested for sensitivity to chemotherapeutic agents, demonstrating that BRCA2-deficient pancreatic tumors exhibit increased sensitivity to cisplatin and PARP inhibitors [183]. The gene discussed is BRCA2; the disease is pancreatic neoplasm.